Outcomes of a Bladder Cancer Screening Program Using Home Hematuria Testing and Molecular Markers - Bangma, Chris H.; Loeb, Stacy; Busstra, Martijn; Zhu, Xiaoye; El Bouazzaoui, Samira; Refos, Jeanine; Van Der Keur, Kirstin A.; Tjin, Stephen; Franken, Conja G.A.M.; van Leenders, Geert J.L.H.; Zwarthoff, Ellen C.; Roobol, Monique J. (European urology, 2013)
Keywords: Aged; Biological and medical sciences; Biomarkers - urine; Bladder cancer; Chi-Square Distribution; Cystoscopy; DNA Methylation; Feasibility Studies; Genetic Markers; Genetic Testing - instrumentation; Hematuria; Hematuria - diagnosis; Hematuria - etiology; Hematuria - genetics; Humans; Male; Mass Screening - instrumentation; Mass Screening - methods; Medical sciences; Microsatellite Instability; Middle Aged; Nephrology. Urinary tract diseases; Netherlands; NMP22, FGFR3, cystoscopy; Nuclear Proteins - urine; Patient Selection; Predictive Value of Tests; Prognosis; Reagent Strips; Receptor, Fibroblast Growth Factor, Type 3 - genetics; Registries; Reproducibility of Results; Risk Assessment; Risk Factors; Screening; Self Care - instrumentation; Tumors of the urinary system; Unnecessary Procedures; Urinalysis - instrumentation; Urinary Bladder Neoplasms - complications; Urinary Bladder Neoplasms - diagnosis; Urinary Bladder Neoplasms - genetics; Urinary Bladder Neoplasms - urine; Urinary system involvement in other diseases. Miscellaneous; Urinary tract. Prostate gland; Urology; Netherlands; Screening; Hematuria; NMP22, FGFR3, cystoscopy; Bladder cancer; Nephrology; Urinary system disease; Program; Prognosis; Genetic marker; Cystoscopy; Urinary tract disease; Malignant tumor; Molecular marker; Medical screening; Hemorrhage; Urology; Bladder disease; Cancer; Fibroblast growth factor receptor 3